Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
نویسندگان
چکیده
منابع مشابه
Mycosis fungoides: cutaneous T-cell lymphoma.
Most patients with mycosis fungoides are between 40 and 60 years of age. The disease has three clinical stages: (1) the premycotic, or patch, stage, consisting of macular, scaling, faint pink to red pruritic patches, usually on unexposed surfaces; (2) the mycotic, or plaque, stage, consisting of reddish, purple-brown plaques, often annular in shape and symmetric in distribution, and (3) the tum...
متن کاملCutaneous T-Cell Lymphoma (Mycosis Fungoides).
IT IS IMPORTANT YOU DO NOT ACCEPT THE DIRE PROGNOSIS given in older medical literature you may find in a public library. Patients diagnosed and treated at early stages of CTCL can usually expect to live a NORMAL LIFESPAN and die of unrelated causes. For others, however, relapses are common, and treatment must either be lifelong in order to control the disease, or it must be repeated each time a...
متن کاملA phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma Jonathon B. Cohen, Kami J. Maddocks, Ying Huang, Beth A. Christian, Samantha M. Jaglowski, Christopher R. Flowers & Kristie A. Blum To cite this article: Jonathon B. Cohen, Kami J. Maddocks, Ying Huang, Beth A. Christian, Samantha M. Jaglowski, Christopher R. Flowers & Kristie A. Blum (2017): A phase...
متن کاملTherapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Peripheral T-cell lymphoma (PTCL) represents a relatively rare group of heterogeneous non-Hodgkin lymphomas with a very poor prognosis. Current therapies, based on historical regimens for aggressive B-cell lymphomas, have resulted in insufficient patient outcomes. The majority of patients relapse rapidly, and current 5-year overall survival rates are only 10-30%. It is evident that new approach...
متن کاملBelinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) represent an uncommon heterogenous group of neoplasms that make up approximately 10% to 15% of non-Hodgkin lymphomas. PTCL, not otherwise specified (NOS) is the most common form, whose incidence in the United States has been increasing, possibly due to better diagnostic methods. PTCLs represent a rare and aggressive subgroup of NHLs that do not respond favora...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Oncology
سال: 2015
ISSN: 0732-183X,1527-7755
DOI: 10.1200/jco.2014.60.6327